NDA 215760 · Orphalan
Cuvrior
Trientine Tetrahydrochloride · Oral
OrphanLast checked: Nov 19, 2026Latest source record: Apr 28, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2022
Apr 28, 2022
Approved uses
1
Original approval plus efficacy supplements
Registered trials
3
2 Phase 3, 1 recruiting
FAERS reports
307
106 serious, 13 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jun 19, 2025.
CUVRIOR is indicated for the treatment of adult patients with stable Wilson's disease who are de-coppered and tolerant to penicillamine. CUVRIOR is a copper chelator indicated for the treatment of adult patients with stable Wilson's disease who are de-coppered and tolerant to penicillamine. ( 1 )
Mechanism: Trientine, a copper chelator, eliminates absorbed copper from the body by forming a stable complex that is then eliminated through urinary excretion. Trientine also chelates copper in the intestinal tract, reducing copper absorption.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- CUVRIOR · TRIENTINE TETRAHYDROCHLORIDE 300MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Trientine Tetrahydrochloride" as an intervention, any sponsor and status, largest first.
- Trientine Tetrahydrochloride (TETA 4HCL) for the Treatment of Wilson's DiseasePivotal-lookingCompleted
OrphalanIndustry
NCT03539952 · 77 participants · Start Sep 3, 2018 · Primary completion Aug 19, 2020
Drug: Penicillamine (D1-W12); TETA 4HCL (W12-60) and 2 more · For: Wilson Disease
Sites: New Haven, Connecticut; Leuven, Belgium; Curitiba, Brazil · 15 sites in all
- Trientine Tetrahydrochloride Administered Once a Day for the First Line Treatment of Wilson's Disease Patients.Pivotal-lookingRecruiting
OrphalanIndustry
NCT07465718 · 38 participants (planned) · Start Sep 3, 2026 · Primary completion Feb 2028
Drug: TETA 4HCl formulation; D-Penicillamine · For: Wilson's Disease
Sites: Denver, Colorado; New Haven, Connecticut; Ann Arbor, Michigan · 10 sites in all
OrphalanIndustry
NCT07010575 · 10 participants · Start Jul 15, 2025 · Primary completion Dec 18, 2025
Drug: New TETA 4HCl Formulation; Standard of Care · For: Wilson's Disease
Sites: Hartshorne, United Kingdom
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use79
- product dose omission issue71
- nausea22
- treatment noncompliance21
- malaise10
- abdominal pain upper9
- fatigue9
- maternal exposure during pregnancy9
- nasopharyngitis9
- vomiting9
- abdominal pain8
- tremor8
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2017 | 1 |
| 2022 | 2 |
| 2023 | 21 |
| 2024 | 86 |
| 2025 | 162 |
| 2026 | 35 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Cuvrior (Trientine Tetrahydrochloride)
2024 spending
$1.6M
Beneficiaries
13
86 claims
Per beneficiary
$119,998
$201.86 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $378,237 |
| 2024 | $1,559,973 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Trientine tetrahydrochloride versus penicillamine for maintenance therapy in Wilson disease (CHELATE): a randomised, open-label, non-inferiority, phase 3 trial.
Schilsky ML, Czlonkowska A, Zuin M, et al. · Lancet Gastroenterol Hepatol 2022 · Clinical Trial, Phase III, Equivalence Trial
- Comparison of the Pharmacokinetic Profiles of Trientine Tetrahydrochloride and Trientine Dihydrochloride in Healthy Subjects.
Weiss KH, Thompson C, Dogterom P, et al. · Eur J Drug Metab Pharmacokinet 2021 · Clinical Trial, Phase I, Comparative Study
- Evaluation of novel assays of non-ceruloplasmin copper to monitor chelation treatment in patients with Wilson disease.
Ott P, Sandahl T, Ala A, et al. · JHEP Rep 2026 · Randomized Controlled Trial
Sponsor: Orphalan
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.